Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 800 participants.

Also called NCT02094963

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 800 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02094963
Other papers using this trial's data
  • Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial Circulation, 2019-12-03 DOI, PubMed 31553203

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02094963. Randomized; no masking; primary purpose treatment. Start 2014-07-05 (actual); primary completion 2018-11-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management
Acronym
TICA KOREA
Condition
Acute Coronary Syndrome
Condition
Myocardial Ischemia
Condition
Heart Diseases
Condition
Cardiovascular Diseases
Condition
Angina Pectoris
Intervention (Drug)
Ticagrelor
Intervention (Drug)
Clopidogrel
Lead sponsor
Seung-Jung Park (class: other)
Collaborator
CardioVascular Research Foundation, Korea (class: other)

Record details

Record id
cardio:ct-nct02094963
Content hash
6020320310b702486a54fee260b02a6d98424389abf72c3bbd3b22ca16571d4c